BCL2 and non-small cell lung carcinoma: In agreement with this finding, Xiao et al. (2017) reported that RAP1, which is highly expressed in NSCLC cells, facilitates NF-κB activation and subsequently induces BCL-2 expression, thus mediating the resistance of NSCLC cells to cisplatin [27].